VIVO CAPITAL LLC
Q3 2026 Form 13-F

PALO ALTO, CALIFORNIA
CIK 0001674712 · CRD 159868 · SEC-registered investment adviser
$908.7M Reported Value Total

VIVO CAPITAL, LLC reports 16 total accounts under management (AUM). There are 16 discretionary accounts valued at $6,095,582,206, and 0 non-discretionary accounts.

Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
SEC Registered Discretionary Manager
Private funds (Form ADV)
29 funds · $7.5B gross asset value
Private Equity Fund: $4.4B · Other: $2.2B · Venture Capital Fund: $899.0M · Securitized Asset Fund: $49.8M
Source: Form ADV filed 2026-03-31
Reported value
$908.7M
Quarter over quarter
-17.3%
Holdings
50
Top-10 concentration
51.3%

Key People

Form ADV owners & control persons
Frank Fang-Chien Kung
MANAGING PARTNER
Edgar George Engleman
MANAGING PARTNER
Shan (nmn) Fu
MANAGING PARTNER

Filing Navigation

13F Metrics

Loading 13F Metrics

Q3 2026 13F record

Q3 2026 13F filing summary

Q3 2026 Form 13F portfolio summary
Period of report September 30, 2026
Filed November 13, 2026
Form 13F-HR
Reported value $908.7M
Positions 50
Change in reported value -17.0%
New positions 8
Exited positions 5
Position turnover 23.6%
Top-10 concentration 51.3%

13F filings by quarter

Form 13F filings by quarter
Quarter Positions Value
Q3 2026 13F
Filed Nov 13, 2026
50 $908.7M
Q2 2026 13F
Filed Aug 14, 2026
47 $1.1B
Q1 2026 13F
Filed May 15, 2026
46 $1.2B
Q4 2025 13F
Filed Feb 13, 2026
47 $1.5B
Q3 2025 13F
Filed Nov 14, 2025
47 $1.2B
Q2 2025 13F
Filed Aug 14, 2025
42 $977.1M
Q1 2025 13F
Filed May 12, 2025
40 $755.1M
Q4 2024 13F
Filed Feb 13, 2025
40 $892.6M
Q3 2024 13F
Filed Nov 13, 2024
43 $1.2B
Q2 2024 13F
Filed Aug 14, 2024
42 $1.1B
Q1 2024 13F
Filed Apr 22, 2024
42 $1.3B
Q4 2023 13F
Filed Feb 7, 2024
47 $1.2B
Q3 2023 13F
Filed Nov 8, 2023
53 $912.8M
Q2 2023 13F
Filed Aug 14, 2023
48 $1.4B
Q1 2023 13F
Filed May 15, 2023
48 $1.4B
Q4 2022 13F
Filed Feb 13, 2023
48 $868.5M
Q3 2022 13F
Filed Nov 14, 2022
51 $905.8M
Q2 2022 13F
Filed Aug 15, 2022
49 $995.9M
Q1 2022 13F
Filed May 13, 2022
54 $1.5B
Q4 2021 13F
Filed Feb 11, 2022
55 $1.7B

23 earlier quarters on file — choose one from the quarter menu above.

Top 20 holdings · Q3 2026

Largest Q3 2026 13F positions by reported value
# Holding Reported value % of portfolio
1 PRAX Praxis Precision Medicines $79.0M 8.69%
2 TRVI Trevi Therapeutics Inc $60.6M 6.67%
3 ERAS Erasca Inc $58.9M 6.49%
4 AVBP Arrivent BioPharma Inc $54.1M 5.95%
5 ABVX Abivax SA $41.1M 4.52%
6 ENTX Entera Bio Ltd $35.7M 3.92%
7 ACRS Aclaris Therapeutics Inc $35.2M 3.88%
8 ANRO Alto Neuroscience Inc $34.7M 3.82%
9 TNGX Tango Therapeutics Inc $34.4M 3.79%
10 CRVS Corvus Pharmaceuticals Inc $32.3M 3.56%
11 LBRX LB Pharmaceuticals Inc $30.7M 3.38%
12 KRSA Korsana Biosciences Inc $28.1M 3.09%
13 BLSM Blossomhill Therapeutics Inc $27.8M 3.06%
14 SNSE Faeth Therapeutics Inc $25.1M 2.76%
15 CAMP CAMP4 Therapeutics Corporation $22.6M 2.48%
16 ACHV Achieve Life Science Inc $22.3M 2.45%
17 SABS SAB Biotherapeutics Inc $21.9M 2.41%
18 DBVT DBV Technologies SA $21.7M 2.39%
19 DRUG Bright Minds Biosciences Inc $20.8M 2.29%
20 DSGN Design Therapeutics Inc $20.3M 2.23%

Values as reported on the Q3 2026 Form 13F. Every position is in the holdings table below.

Filing Details

Loading Activities
Loading Sector Allocation
Crunching numbers

Performance

Loading Performance

Similar Managers

Finding Similar Managers

Potential New Buys

Finding Potential New Buys

Holdings

Building table
Loading SEC filing data
Loading Form 4 Filings

Beneficial Ownership (Schedule 13D/13G)

Loading 13D/G filings